It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

A triad of growth drivers and a long track record of operational excellence will ensure this company's admittance into an ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research ...

Wall Street's major averages ended mixed on Monday, with the Nasdaq Composite and the S&P 500 managing to advance as big tech ...

Cigna Group (NYSE:CI) Chairman and CEO David Cordani reported purchasing 4,134 shares of the company’s common stock on November 3, 2025, for a total value of $999,916. The price per share for this ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of ...

A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot ...

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical ...

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is ...

Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...